RS58870B1 - Jedinjenje pirazola i njegova farmaceutska upotreba - Google Patents

Jedinjenje pirazola i njegova farmaceutska upotreba

Info

Publication number
RS58870B1
RS58870B1 RS20190581A RSP20190581A RS58870B1 RS 58870 B1 RS58870 B1 RS 58870B1 RS 20190581 A RS20190581 A RS 20190581A RS P20190581 A RSP20190581 A RS P20190581A RS 58870 B1 RS58870 B1 RS 58870B1
Authority
RS
Serbia
Prior art keywords
group
compound
6alkyl
halo
6alkoxy
Prior art date
Application number
RS20190581A
Other languages
English (en)
Serbian (sr)
Inventor
Tomoya Miura
Yosuke Ogoshi
Kazuhito Ueyama
Dai Motoda
Toshihiko Iwayama
Koichi Suzawa
Hironobu Nagamori
Hiroshi Ueno
Akihiko Takahashi
Kazuyuki Sugimoto
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of RS58870B1 publication Critical patent/RS58870B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20190581A 2011-08-31 2012-08-30 Jedinjenje pirazola i njegova farmaceutska upotreba RS58870B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011188121 2011-08-31
US201161573433P 2011-09-06 2011-09-06
EP17157922.0A EP3199533B1 (en) 2011-08-31 2012-08-30 Pyrazole compound and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
RS58870B1 true RS58870B1 (sr) 2019-08-30

Family

ID=47756400

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190581A RS58870B1 (sr) 2011-08-31 2012-08-30 Jedinjenje pirazola i njegova farmaceutska upotreba

Country Status (28)

Country Link
US (5) US8846746B2 (enExample)
EP (4) EP2784074A4 (enExample)
JP (6) JP6091811B2 (enExample)
KR (1) KR101989203B1 (enExample)
CN (1) CN103917535B (enExample)
AR (2) AR087701A1 (enExample)
AU (1) AU2012302723B2 (enExample)
BR (1) BR112014004651B1 (enExample)
CA (1) CA2845127C (enExample)
CL (1) CL2014000490A1 (enExample)
CO (1) CO6890098A2 (enExample)
CY (1) CY1121631T1 (enExample)
DK (1) DK3199533T3 (enExample)
HK (1) HK1202290A1 (enExample)
IL (1) IL230763A (enExample)
MX (1) MX359825B (enExample)
MY (1) MY172422A (enExample)
PE (1) PE20142343A1 (enExample)
PH (1) PH12014500444A1 (enExample)
PL (1) PL3199533T3 (enExample)
RS (1) RS58870B1 (enExample)
RU (1) RU2617678C2 (enExample)
SG (1) SG11201400244YA (enExample)
SI (1) SI3199533T1 (enExample)
SM (1) SMT201900292T1 (enExample)
TW (1) TWI549949B (enExample)
WO (1) WO2013031922A1 (enExample)
ZA (1) ZA201401071B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
CA2872002C (en) 2012-05-07 2019-01-15 Masayuki Isaji Pyrazole derivative and use thereof for medical purposes
US9783543B2 (en) 2012-11-19 2017-10-10 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazines
RU2648467C2 (ru) 2013-02-04 2018-03-26 Тайсо Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое лекарственное средство для лечения запора
JP6309080B2 (ja) * 2013-05-08 2018-04-18 ザ ユニバーシティ オブ ヒューストン システム がん治療のためのｅｇｆｒ−ｓｇｌｔ１相互作用の標的化
CN105294703B (zh) * 2015-10-23 2018-01-23 西安近代化学研究所 3,7,10‑三氧代‑2,4,6,8,9,11‑六氮杂[3,3,3]螺桨烷的合成方法
CN109790150A (zh) 2016-08-11 2019-05-21 拜耳作物科学股份公司 取代的吡唑啉基衍生物、其制备方法及其作为除草剂和/或植物生长调节剂的用途
ES2863853T3 (es) 2016-08-15 2021-10-11 Bayer Cropscience Ag Procedimiento para la preparación de 3-amino-1-(2,6-disustituido-fenil)pirazoles
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
CA3089092A1 (en) * 2018-04-04 2019-10-10 Japan Tobacco Inc. Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
CN119113123A (zh) * 2019-09-04 2024-12-13 日本烟草产业株式会社 利用联用药物的糖尿病的治疗或预防方法
JP7760370B2 (ja) * 2019-09-04 2025-10-27 日本たばこ産業株式会社 慢性腎臓病の治療又は予防方法
AU2021237149A1 (en) * 2020-03-19 2022-10-06 Japan Tobacco Inc. Treatment or prevention method for chronic heart failure

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
BR0013143A (pt) * 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
NZ538117A (en) * 2002-08-08 2007-01-26 Kissei Pharmaceutical Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
AP2007003979A0 (en) 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
TWI378922B (en) * 2005-10-21 2012-12-11 Mitsubishi Tanabe Pharma Corp A pyrazole compound
JP5069894B2 (ja) 2005-10-21 2012-11-07 田辺三菱製薬株式会社 ピラゾール化合物
WO2007046550A1 (en) 2005-10-21 2007-04-26 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity
US20070117858A1 (en) 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
WO2008045484A1 (en) * 2006-10-10 2008-04-17 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP2010222298A (ja) 2009-03-24 2010-10-07 Shionogi & Co Ltd Ｎｐｙｙ５受容体拮抗作用を有するピロリドン誘導体
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
CA2829790C (en) 2010-03-30 2018-06-05 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
WO2012002527A1 (ja) 2010-07-02 2012-01-05 あすか製薬株式会社 複素環化合物及びｐ２７Ｋｉｐ１分解阻害剤
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1

Also Published As

Publication number Publication date
CL2014000490A1 (es) 2014-08-22
US8846746B2 (en) 2014-09-30
CO6890098A2 (es) 2014-03-10
US20130085132A1 (en) 2013-04-04
BR112014004651B1 (pt) 2021-08-31
MX359825B (es) 2018-10-10
CN103917535B (zh) 2015-06-24
SG11201400244YA (en) 2014-10-30
IL230763A (en) 2016-10-31
CA2845127C (en) 2020-03-10
JP2020125348A (ja) 2020-08-20
EP3199533B1 (en) 2019-02-27
JP2025039641A (ja) 2025-03-21
MX2014002552A (es) 2014-04-25
SI3199533T1 (sl) 2019-06-28
IL230763A0 (en) 2014-03-31
TW201321372A (zh) 2013-06-01
JP2023087032A (ja) 2023-06-22
MY172422A (en) 2019-11-25
AU2012302723A1 (en) 2014-02-27
WO2013031922A1 (ja) 2013-03-07
US20150183763A1 (en) 2015-07-02
NZ620977A (en) 2016-02-26
US20230348438A1 (en) 2023-11-02
HK1202290A1 (en) 2015-09-25
BR112014004651A2 (pt) 2017-03-28
DK3199533T3 (da) 2019-05-20
AR123441A2 (es) 2022-11-30
PL3199533T3 (pl) 2019-09-30
EP2784074A4 (en) 2015-06-03
EP4656638A2 (en) 2025-12-03
AR087701A1 (es) 2014-04-09
CN103917535A (zh) 2014-07-09
KR20140062048A (ko) 2014-05-22
EP3199533A1 (en) 2017-08-02
JP6091811B2 (ja) 2017-03-08
RU2617678C2 (ru) 2017-04-26
PH12014500444A1 (en) 2017-04-07
US20180346449A1 (en) 2018-12-06
CA2845127A1 (en) 2013-03-07
KR101989203B1 (ko) 2019-06-13
JP2017082005A (ja) 2017-05-18
JP2018115216A (ja) 2018-07-26
ZA201401071B (en) 2016-10-26
CY1121631T1 (el) 2020-07-31
US20200317644A1 (en) 2020-10-08
EP2784074A1 (en) 2014-10-01
SMT201900292T1 (it) 2019-07-11
RU2014112048A (ru) 2015-10-10
AU2012302723B2 (en) 2016-08-11
EP3524599A1 (en) 2019-08-14
JP2013063968A (ja) 2013-04-11
PE20142343A1 (es) 2015-01-29
TWI549949B (zh) 2016-09-21

Similar Documents

Publication Publication Date Title
RS58870B1 (sr) Jedinjenje pirazola i njegova farmaceutska upotreba
CN113811300B (zh) Tead转录因子的新型小分子抑制剂
KR101088247B1 (ko) 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도
EP3307727B1 (en) Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer
CN102838546A (zh) 作为5-ht2a 血清素受体调节剂用于治疗与其相关病症的吡唑衍生物
TW200922556A (en) Novel cathepsin C inhibitors and their use
ES2320030T3 (es) Derivados de amida del 5-amino-4-hidroxi-8-(1h-indol-5-ilo) octan 2,7-sustituidos como inhibidores de la renina para el tratamiento de la hipertension.
WO2014042238A1 (ja) スルホンアミド化合物
CN115551846A (zh) 1,4,5,6-四氢嘧啶-2-胺衍生物
HK1242309B (en) Pyrazole compound and pharmaceutical use thereof
HK1242309A1 (en) Pyrazole compound and pharmaceutical use thereof
NZ620977B2 (en) Pyrazole compound and use thereof for medical purposes
JP2011079777A (ja) システインプロテアーゼ阻害剤